vs
Side-by-side financial comparison of LENZ Therapeutics, Inc. (LENZ) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
Americas Gold & Silver Corp is the larger business by last-quarter revenue ($19.1M vs $12.5M, roughly 1.5× LENZ Therapeutics, Inc.). Americas Gold & Silver Corp runs the higher net margin — -82.3% vs -133.6%, a 51.3% gap on every dollar of revenue. LENZ Therapeutics, Inc. produced more free cash flow last quarter ($-9.0M vs $-41.3M).
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing novel ophthalmic therapies. Its lead product candidates address presbyopia, the age-related loss of near vision, catering to global patient groups with unmet medical needs in the eye care sector.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
LENZ vs USAS — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $19.1M |
| Net Profit | $-16.7M | $-15.7M |
| Gross Margin | — | 34.2% |
| Operating Margin | -151.1% | — |
| Net Margin | -133.6% | -82.3% |
| Revenue YoY | — | -28.0% |
| Net Profit YoY | -63.5% | 2.8% |
| EPS (diluted) | $-0.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $12.5M | $19.1M | ||
| Q2 25 | $5.0M | — | ||
| Q3 24 | $0 | $26.5M | ||
| Q2 24 | $0 | — |
| Q3 25 | $-16.7M | $-15.7M | ||
| Q2 25 | $-14.9M | — | ||
| Q3 24 | $-10.2M | $-16.2M | ||
| Q2 24 | $-10.3M | — |
| Q3 25 | — | 34.2% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | 23.6% | ||
| Q2 24 | — | — |
| Q3 25 | -151.1% | — | ||
| Q2 25 | -337.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | -133.6% | -82.3% | ||
| Q2 25 | -298.2% | — | ||
| Q3 24 | — | -60.9% | ||
| Q2 24 | — | — |
| Q3 25 | $-0.59 | — | ||
| Q2 25 | $-0.53 | — | ||
| Q3 24 | $-0.38 | — | ||
| Q2 24 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.4M | $39.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $193.9M | $50.2M |
| Total Assets | $210.7M | $234.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $25.4M | $39.1M | ||
| Q2 25 | $37.6M | — | ||
| Q3 24 | $41.0M | — | ||
| Q2 24 | $84.0M | — |
| Q3 25 | $193.9M | $50.2M | ||
| Q2 25 | $206.4M | — | ||
| Q3 24 | $215.3M | $53.1M | ||
| Q2 24 | $192.9M | — |
| Q3 25 | $210.7M | $234.7M | ||
| Q2 25 | $217.3M | — | ||
| Q3 24 | $224.0M | — | ||
| Q2 24 | $202.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-12.5M |
| Free Cash FlowOCF − Capex | $-9.0M | $-41.3M |
| FCF MarginFCF / Revenue | -72.2% | -216.5% |
| Capex IntensityCapex / Revenue | 3.5% | 150.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-47.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-8.6M | $-12.5M | ||
| Q2 25 | $-11.5M | — | ||
| Q3 24 | $-10.6M | $2.4M | ||
| Q2 24 | $-15.8M | — |
| Q3 25 | $-9.0M | $-41.3M | ||
| Q2 25 | $-11.7M | — | ||
| Q3 24 | $-10.8M | $-11.2M | ||
| Q2 24 | $-15.9M | — |
| Q3 25 | -72.2% | -216.5% | ||
| Q2 25 | -235.0% | — | ||
| Q3 24 | — | -42.2% | ||
| Q2 24 | — | — |
| Q3 25 | 3.5% | 150.8% | ||
| Q2 25 | 4.8% | — | ||
| Q3 24 | — | 51.2% | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
